Immunic, Inc. (IMUX)
16.50
0.00 (0.00%)
USD |
NASDAQ |
Aug 24, 16:00
16.50
0.00 (0.00%)
After-Hours: 20:00
Immunic EPS Diluted (Quarterly) : -0.8021 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.8021 |
| March 31, 2026 | -1.081 |
| December 31, 2025 | -1.603 |
| September 30, 2025 | -1.319 |
| June 30, 2025 | -2.029 |
| March 31, 2025 | -2.514 |
| December 31, 2024 | -2.792 |
| September 30, 2024 | -0.2406 |
| June 30, 2024 | -0.2111 |
| March 31, 2024 | -0.304 |
| December 31, 2023 | -0.4833 |
| September 30, 2023 | -0.5108 |
| June 30, 2023 | -0.5401 |
| March 31, 2023 | -0.5788 |
| December 31, 2022 | -1.628 |
| September 30, 2022 | -0.6944 |
| June 30, 2022 | -0.724 |
| March 31, 2022 | -0.7398 |
| December 31, 2021 | -0.8044 |
| September 30, 2021 | -0.7619 |
| June 30, 2021 | -0.8246 |
| March 31, 2021 | -1.631 |
| December 31, 2020 | -0.5272 |
| September 30, 2020 | -0.7016 |
| June 30, 2020 | -0.9025 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.7895 |
| December 31, 2019 | -0.75 |
| September 30, 2019 | -0.8196 |
| June 30, 2019 | -1.522 |
| March 31, 2019 | -2036.95 |
| December 31, 2018 | -56.82 |
| September 30, 2018 | -21.22 |
| June 30, 2018 | -31.52 |
| March 31, 2018 | -13.60 |
| December 31, 2017 | -14.00 |
| September 30, 2017 | -12.00 |
| June 30, 2017 | -116.00 |
| March 31, 2017 | -15.60 |
| December 31, 2016 | -14.80 |
| September 30, 2016 | -12.80 |
| June 30, 2016 | -12.00 |
| March 31, 2016 | -12.40 |
| December 31, 2015 | -13.60 |
| September 30, 2015 | -20.40 |
| June 30, 2015 | -25.20 |
| March 31, 2015 | -24.80 |
| December 31, 2014 | -23.60 |
| September 30, 2014 | -23.60 |
| June 30, 2014 | -36.40 |
| March 31, 2014 | -979.60 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Sionna Therapeutics, Inc. | -0.6619 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -34.10M |
| Total Expenses (Quarterly) | 34.10M |
| Enterprise Value | 70.60M |
| Earnings Yield | -29.13% |
| Normalized Earnings Yield | -29.13 |